JP2020517648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517648A5 JP2020517648A5 JP2019556938A JP2019556938A JP2020517648A5 JP 2020517648 A5 JP2020517648 A5 JP 2020517648A5 JP 2019556938 A JP2019556938 A JP 2019556938A JP 2019556938 A JP2019556938 A JP 2019556938A JP 2020517648 A5 JP2020517648 A5 JP 2020517648A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- patient
- composition according
- administered
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims 6
- 201000006417 multiple sclerosis Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims 3
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims 3
- 238000010254 subcutaneous injection Methods 0.000 claims 3
- 239000007929 subcutaneous injection Substances 0.000 claims 3
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 102000013135 CD52 Antigen Human genes 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 230000001754 anti-pyretic effect Effects 0.000 claims 2
- 229940125715 antihistaminic agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 239000002221 antipyretic Substances 0.000 claims 2
- 229940125716 antipyretic agent Drugs 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023009976A JP2023052642A (ja) | 2017-04-21 | 2023-01-26 | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488630P | 2017-04-21 | 2017-04-21 | |
| US62/488,630 | 2017-04-21 | ||
| US201762575119P | 2017-10-20 | 2017-10-20 | |
| US62/575,119 | 2017-10-20 | ||
| US201862647301P | 2018-03-23 | 2018-03-23 | |
| US62/647,301 | 2018-03-23 | ||
| PCT/US2018/028616 WO2018195457A2 (en) | 2017-04-21 | 2018-04-20 | Treatment of multiple sclerosis with anti-cd52 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009976A Division JP2023052642A (ja) | 2017-04-21 | 2023-01-26 | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020517648A JP2020517648A (ja) | 2020-06-18 |
| JP2020517648A5 true JP2020517648A5 (enExample) | 2021-05-27 |
| JP7219721B2 JP7219721B2 (ja) | 2023-02-08 |
Family
ID=62117065
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556938A Active JP7219721B2 (ja) | 2017-04-21 | 2018-04-20 | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
| JP2023009976A Abandoned JP2023052642A (ja) | 2017-04-21 | 2023-01-26 | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023009976A Abandoned JP2023052642A (ja) | 2017-04-21 | 2023-01-26 | 抗ｃｄ５２抗体を用いて多発性硬化症を処置するための経路およびスケジュール |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20200299399A1 (enExample) |
| EP (1) | EP3612564A2 (enExample) |
| JP (2) | JP7219721B2 (enExample) |
| CN (1) | CN110546167A (enExample) |
| TW (1) | TW201841653A (enExample) |
| WO (1) | WO2018195457A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY160126A (en) | 2009-05-13 | 2017-02-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9498528B2 (en) * | 2006-09-13 | 2016-11-22 | Genzyme Corporation | Treatment of multiple sclerosis (MS) |
| HUE026740T2 (en) * | 2006-09-13 | 2016-07-28 | Alcafleu Man Gmbh & Co Kg | Treatment of Multiple Sclerosis (MS) with Campath-1H |
| MY160126A (en) | 2009-05-13 | 2017-02-28 | Genzyme Corp | Anti-human cd52 immunoglobulins |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| EP3027187A4 (en) * | 2013-08-01 | 2017-03-29 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy |
| CA3205824A1 (en) * | 2014-10-09 | 2016-04-14 | Genzyme Corporation | Glycoengineered antibody drug conjugates |
-
2018
- 2018-04-20 TW TW107113566A patent/TW201841653A/zh unknown
- 2018-04-20 US US16/606,622 patent/US20200299399A1/en not_active Abandoned
- 2018-04-20 CN CN201880026423.7A patent/CN110546167A/zh active Pending
- 2018-04-20 WO PCT/US2018/028616 patent/WO2018195457A2/en not_active Ceased
- 2018-04-20 JP JP2019556938A patent/JP7219721B2/ja active Active
- 2018-04-20 EP EP18723220.2A patent/EP3612564A2/en not_active Withdrawn
-
2022
- 2022-09-09 US US17/930,867 patent/US20230167189A1/en not_active Abandoned
-
2023
- 2023-01-26 JP JP2023009976A patent/JP2023052642A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025138634A (ja) | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 | |
| JP2022023051A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2019515008A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2014533279A5 (enExample) | ||
| JP2018518454A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2017537105A5 (enExample) | ||
| CN101657215A (zh) | 在诊断和治疗类风湿性关节炎中使用的包含抗-cd6单克隆抗体的药物组合物 | |
| JP2018529661A5 (enExample) | ||
| JP2019528306A5 (enExample) | ||
| US20250075007A1 (en) | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells | |
| JP2018512402A5 (enExample) | ||
| JP2024069230A5 (enExample) | ||
| JP2019521156A5 (enExample) | ||
| JP2021506817A5 (enExample) | ||
| JPWO2019160755A5 (enExample) | ||
| JP2023138982A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法 | |
| CN115052628A (zh) | 抗pd-1抗体在治疗肿瘤中的用途 | |
| JP2020505350A5 (enExample) | ||
| JP2020517648A5 (enExample) | ||
| JPWO2021224499A5 (enExample) | ||
| JP2019535716A5 (enExample) | ||
| AU2023270497A1 (en) | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |